Mutual of America Capital Management LLC Lowers Position in United Therapeutics Co. (NASDAQ:UTHR)

Mutual of America Capital Management LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 9.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,398 shares of the biotechnology company’s stock after selling 2,603 shares during the period. Mutual of America Capital Management LLC owned about 0.06% of United Therapeutics worth $8,091,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in UTHR. ClariVest Asset Management LLC boosted its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares in the last quarter. Access Investment Management LLC boosted its holdings in United Therapeutics by 0.8% during the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock worth $2,314,000 after buying an additional 55 shares in the last quarter. MBM Wealth Consultants LLC boosted its holdings in United Therapeutics by 2.7% during the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after buying an additional 59 shares in the last quarter. Fifth Third Bancorp boosted its holdings in United Therapeutics by 13.2% during the second quarter. Fifth Third Bancorp now owns 585 shares of the biotechnology company’s stock worth $186,000 after buying an additional 68 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in United Therapeutics by 3.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company’s stock worth $849,000 after buying an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $351.33 on Friday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $366.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The company has a 50 day moving average price of $338.00 and a 200 day moving average price of $289.96. The firm has a market capitalization of $15.63 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period last year, the company posted $5.24 EPS. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. Sell-side analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current year.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,076.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $41,076.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,922 shares of company stock valued at $36,541,398. Insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on UTHR shares. LADENBURG THALM/SH SH downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. UBS Group upped their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Oppenheimer upped their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. Finally, Bank of America reduced their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.